Drug Patents owned by Genentech Inc
1. Drug name - COTELLIC
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(7 years from now) | |
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(13 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(13 years from now) | |
| CN103524392A | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN104892582B | GENENTECH INC | As Arylmethylazetidine For Mek Inhibitor For Treating Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN104892582A | GENENTECH INC | As Azetidine Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN101365676B | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN109053523A | GENENTECH INC | As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine |
Oct, 2026
(4 years from now) | |
| CN109053523B | GENENTECH INC | Azdines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN103524392B | GENENTECH INC | As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine |
Oct, 2026
(4 years from now) | |
| CN101365676A | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| CN108135854B | GENENTECH INC | Immediate Release Tablet Containing Medicine And Method For Forming Tablet |
Jun, 2036
(13 years from now) | |
| CN108135854A | GENENTECH INC | Drug-Containing Immediate Release Tablets And A Method Of Forming A Tablet |
Jun, 2036
(13 years from now) | |
| IN200802771P1 | GENENTECH INC | Mek Inhibitors And Methods Of Thier Use |
Oct, 2026
(4 years from now) | |
| IN313177B | GENENTECH INC | Mek Inhibitors And Methods Of Thier Use |
Oct, 2026
(4 years from now) | |
| EP1934174B1 | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| EP1934174A1 | GENENTECH INC | Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases |
Oct, 2026
(4 years from now) | |
| EP3316867A1 | GENENTECH INC | Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets |
Jun, 2036
(13 years from now) | |
| EP3316867B1 | GENENTECH INC | Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets |
Jun, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(4 years from now) | |
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(11 years from now) | |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
2. Drug name - ESBRIET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
| US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
| US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
| US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(3 years from now) | |
| US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(5 years from now) | |
| US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(5 years from now) | |
| US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(5 years from now) | |
| US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
| US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
| US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
| US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(6 years from now) | |
| US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(7 years from now) | |
| US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(7 years from now) | |
| US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(7 years from now) | |
| US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(7 years from now) | |
| US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(7 years from now) | |
| US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(7 years from now) | |
| US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(7 years from now) | |
| US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(10 years from now) | |
| US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(14 years from now) | |
Drugs and Companies using PIRFENIDONE ingredient
Treatment: Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis; Method of administering pirfenidone capsules to treat a fibrotic condition; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis; Dose escalation over 14 days for treatment of a fibrosis condition; Dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by administering a sub-1600 mg/day dose, followed by administering at least 1602 mg/day; dosing at least 1602 mg/day following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration; dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone, followed by administering at least 1602 mg/day; full daily dosing following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration; dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by administering sub-2400 mg/day dose, followed by full daily dose; dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose; dosage modification following grade 2 abnormality in biomarker alt or ast after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then sub-1600 mg/day, then at least 1602 mg/day; Dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by 801 mg/day, dose, then 1602 mg/day in treatment of ipf; full daily dosing following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering full daily dose in treatment of ipf; dosing 1602 mg/day pirfenidone following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering 801 mg/day followed by administering 1602 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits followed by administering 1602 mg/day in treatment of ipf; Continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis; Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Method for administering pirfenidone to reduce drug interactions with a strong inhibitor of cyp1a2; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer; Dosage modification in treatment with pirfenidone to reduce drug interactions with ciprofloxacin
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 267MG | TABLET;ORAL | Prescription |
| 534MG | TABLET;ORAL | Discontinued |
| 801MG | TABLET;ORAL | Prescription |
3. Drug name - EVRYSDI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(10 years from now) | |
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(12 years from now) | |
| CN104349777A | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| CN104349777B | GENENTECH INC | For Compound For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| CN106459092B | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
May, 2035
(12 years from now) | |
| CN106459092A | GENENTECH INC | For Compound For Treating Spinal Muscular Atrophy |
May, 2035
(12 years from now) | |
| IN201647038542A | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
May, 2035
(12 years from now) | |
| IN334397B | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
May, 2035
(12 years from now) | |
| EP3406252B1 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| EP2812004A2 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| EP2812004A4 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| EP2812004B1 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| EP3406252A1 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
Feb, 2033
(10 years from now) | |
| EP3143025A1 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
May, 2035
(12 years from now) | |
| EP3143025B1 | GENENTECH INC | Compounds For Treating Spinal Muscular Atrophy |
May, 2035
(12 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.75MG/ML | FOR SOLUTION;ORAL | Prescription |
4. Drug name - GAVRETO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(14 years from now) | |
| CN108473468B | GENENTECH INC | Inhibitors Of Ret |
Nov, 2036
(14 years from now) | |
| CN108473468A | GENENTECH INC | Inhibitors Of Ret |
Nov, 2036
(14 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
5. Drug name - ROZLYTREK
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(6 years from now) | |
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| CN106167485A | GENENTECH INC | Acetamidobenzamide, Compositions Containing Acetamidobenzamide And Preparation Method Of Acetamidobenzamide |
Feb, 2020
(2 years ago) | |
| CN101754956A | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN103923072A | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN103923072B | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN101754956B | GENENTECH INC | Substituted Indazole Derivatives Having Activity Of Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN104395308B | GENENTECH INC | N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method |
May, 2033
(10 years from now) | |
| CN104395308A | GENENTECH INC | N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method |
May, 2033
(10 years from now) | |
| CN109153669B | GENENTECH INC | New Crystal Form Of Benzamide Compound |
May, 2037
(14 years from now) | |
| CN109153669A | GENENTECH INC | N - [5 - (3, 5-Difluoro-Benzyl) -1H - Indazol - -3 - Yl]--4-(4-Methyl-Piperazin - -1 - Yl)--2-(Tetrahydropyran - -4 - Ylamino) - Form |
May, 2037
(14 years from now) | |
| IN281852B | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| IN201000870P4 | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| IN361050B | GENENTECH INC | Process For The Preparation Of N-[5-(3-5-Difluoro Benzyl)-1H-Indazol 3 Yl]- 4-(4 Methyl Piperazin -1- Yl) -2- (Tetrahydro Pyran -4- Ylamino) Benzamide |
May, 2033
(10 years from now) | |
| IN201409107P4 | GENENTECH INC | Process For The Preparation Of N [5 (3 5 Difluoro Benzyl) 1H Indazol 3 Yl] 4 (4 Methyl Piperazin 1 Yl) 2 (Tetrahydro Pyran 4 Ylamino) Benzamide |
May, 2033
(10 years from now) | |
| EP2855460A1 | GENENTECH INC | Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
Oct, 2017
(4 years ago) | |
| EP2176231B1 | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| EP2176231A1 | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| EP3290414B1 | GENENTECH INC | Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3333166B1 | GENENTECH INC | Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3333166A1 | GENENTECH INC | Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3290414A1 | GENENTECH INC | Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3464276A1 | GENENTECH INC | New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide |
May, 2037
(14 years from now) | |
| EP3464276B1 | GENENTECH INC | New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide |
May, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(12 years from now) | |
| US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(12 years from now) | |
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(15 years from now) | |
Drugs and Companies using ENTRECTINIB ingredient
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
| 200MG | CAPSULE;ORAL | Prescription |
6. Drug name - XOFLUZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(8 years from now) | |
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(14 years from now) | |
| CN112876473A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Jun, 2022
(3 months ago) | |
| CN103228653A | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| CN103228653B | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| CN112940010A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN112940010B | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN113004304A | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| CN113004304B | GENENTECH INC | Substituted Polycyclic Pyridone Derivatives And Prodrugs Thereof |
Apr, 2036
(13 years from now) | |
| IN201303057P4 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| IN318238B | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| IN201747041390A | GENENTECH INC | Substituted Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| IN346800B | GENENTECH INC | Substituted Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| EP2620436A1 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| EP2620436A4 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| EP2620436B1 | GENENTECH INC | Substituted Polycyclic Carbamoyl Pyridone Derivative Prodrug |
Sep, 2031
(8 years from now) | |
| EP3428170A1 | GENENTECH INC | Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| EP3428170B1 | GENENTECH INC | Anti-Influenza Polycyclic Pyridone Derivative And Prodrug Thereof |
Apr, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(7 years from now) | |
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(8 years from now) | |
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
Treatment: Method for treating influenza; method for post-exposure prophylaxis of influenza
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
| 80MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.